Publicaciones en colaboración con investigadores/as de Stanford University School of Medicine (9)

2023

  1. Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial

    American Journal of Kidney Diseases, Vol. 82, Núm. 1, pp. 84-96.e1

2022

  1. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

    Kidney International, Vol. 101, Núm. 1, pp. 174-184

2021

  1. Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial

    Circulation, Vol. 143, Núm. 18, pp. 1735-1749

  2. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial

    European Heart Journal, Vol. 42, Núm. 48, pp. 4891-4901

  3. Effects of dapagliflozin in stage 4 chronic kidney disease

    Journal of the American Society of Nephrology, Vol. 32, Núm. 9, pp. 2352-2361

  4. Effects of dapagliflozin on mortality in patients with chronic kidney disease: A pre-specified analysis from the DAPA-CKD randomized controlled trial

    European Heart Journal, Vol. 42, Núm. 13, pp. 1216-1227

2020

  1. Rationale and protocol of the Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

    Nephrology Dialysis Transplantation, Vol. 35, Núm. 2, pp. 274-282

  2. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 35, Núm. 10, pp. 1700-1711

2013

  1. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

    New England Journal of Medicine, Vol. 369, Núm. 26, pp. 2492-2503